Necsa: There’s more to nuclear technology than pure power

South Africa's state-owned Nuclear Energy Corporation (Necsa) is repositioning nuclear technology as far more than a power generation tool. The shift reflects a strategic diversification that unlocks billions in medical, industrial, and agricultural applications—a narrative often overlooked by investors fixated on electricity supply debates.

## What exactly is Necsa's nuclear technology beyond power plants?

Necsa operates the Safari-1 research reactor, Africa's only high-flux facility producing medical radioisotopes, particularly Technetium-99m (Tc-99m), the most widely used diagnostic agent in nuclear medicine globally. The corporation also manufactures Iridium-192 for industrial radiography, Cobalt-60 for cancer treatment, and supplies isotopes to over 100 countries. These applications generate steady, recurring revenue independent of load-shedding crises or renewable energy debates. In 2023, Necsa's isotope production contributed approximately R800 million ($43 million USD) to South African GDP—a fraction of its potential, but strategically significant.

## Why does this matter for African investors and markets?

Africa's healthcare infrastructure faces critical shortages of diagnostic imaging capacity. Nuclear medicine diagnostics cost 40% less than PET-CT alternatives and require minimal infrastructure. South Africa's isotope monopoly in sub-Saharan Africa creates a moat: competing facilities exist only in Belgium, Canada, and Australia. Demand from Nigeria, Kenya, Egypt, and Ghana outpaces supply. Necsa's expansion could capture 30-40% higher volumes within five years, directly supporting regional cancer treatment programs and cardiology diagnostics.

Industrial applications are equally compelling. Irradiation sterilization of medical devices—a non-negotiable requirement for African manufacturers seeking WHO and CE certification—depends entirely on Cobalt-60 supply. Agricultural applications (seed irradiation for pest control and yield improvement) address food security across the continent. Morocco, Egypt, and Kenya have signaled interest in isotope-based crop programs.

## How does Necsa's diversification strengthen South Africa's economic position?

The nuclear sector employs over 12,000 skilled workers and supports a supply chain of engineering firms, logistics providers, and research institutions. Expanding isotope production to meet African demand creates high-value jobs resistant to outsourcing. Unlike volatile commodity exports, isotope production generates predictable, long-cycle contracts—preferred by institutional investors seeking stable cash flows.

Necsa's export revenue is also currency-stable: all sales are denominated in USD or EUR, insulating the corporation from rand volatility. This matters enormously for South Africa's foreign exchange reserves and investor confidence during rand weakness periods.

## What are the near-term catalysts?

Necsa is investing R2 billion ($108 million USD) in Safari-1 upgrades and a new isotope production facility scheduled for completion by 2027. This capital expenditure signals confidence and will drive demand among engineering and construction contractors. Additionally, pending African Union recognition of Necsa as the continent's premier nuclear medicine hub could unlock preferential procurement agreements across 55 member states.

Risks remain: regulatory delays, competing production capacity in Europe, and geopolitical tensions affecting supply chains. However, the strategic case is robust: nuclear medicine is non-discretionary, demand is inelastic, and Africa's supply deficit is acute.

---

#